FDA Approves BOSENTAN — Actavis Pharma, Inc.

# FDA Approves Generic Bosentan The FDA has approved Actavis Pharma, Inc.'s generic formulation of bosentan (ANDA207110), a pulmonary arterial hypertension treatment, potentially opening the market to competitive pricing and increased patient access as the branded Tracleer faces generic competition. The oral medication's approval is expected to drive down treatment costs and expand market share among generic manufacturers in the pulmonary hypertension segment.